Michel Goldman, MD, PhD, is full professor and founder of the Institute for Interdisciplinary Innovation in healthcare (I³h) at the Université Libre de Bruxelles, Belgium. From 2009 to 2014, he served as Executive Director of the Innovative Medicines Initiative (IMI), the public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations. His current research topics include new models for drug pricing and vaccine hesitancy. As an immunologist, he was recognized as ISI Highly Cited Scientist for Scientific Information and shared the Lucien Steinberg Prize in 1992 with Pr. Peter Piot. He held in 2001 the Spinoza chair at the University of Amsterdam. In 2007, Michel Goldman was awarded the degree of Doctor Honoris Causa of the University of Lille.
Scientist: Michel Goldman
A scientist’s opinion : Interview with Professor Michel Goldman about new technologies in medicine
Interview with Michel Goldman, founder of the Institute for Interdisciplinary Innovation in Healthcare (I3H) and former Executive Director of the Innovative Medicines Initiative (IMI). How was the idea of I3H born? Michel Goldman: At the Innovative Medicines Initiative (IMI) the main goal was to bring together pharmaceutical industry and universities, patient organizations, and regulators, to ...
New technologies in medicine: time to prepare
The technological revolution involving artificial intelligence, big data, machine learning and robotics is posed to deeply change healthcare and biomedical research, and things are changing fast. In this rapidly evolving scenario, researchers and health professionals need to acquire new skills and knowledge.
